PRQR
PRQR
NASDAQ · Biotechnology

Proqr Therapeutics Nv

$1.70
+0.10 (+6.25%)
As of May 16, 2:08 AM ET ·
Financial Highlights (FY 2026)
Revenue
15.68M
Net Income
-40,452,130
Gross Margin
Profit Margin
-258.1%
Rev Growth
+50.5%
D/E Ratio
0.32
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 46.9% 46.9%
Operating Margin -265.8% -239.2% 5.6% 5.8%
Profit Margin -258.1% -245.2% 4.3% 4.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 15.68M 10.42M 53.79M 56.60M
Gross Profit 25.23M 26.55M
Operating Income -41,661,656 -24,922,226 2.99M 3.30M
Net Income -40,452,130 -24,198,681 2.31M 2.33M
Gross Margin 46.9% 46.9%
Operating Margin -265.8% -239.2% 5.6% 5.8%
Profit Margin -258.1% -245.2% 4.3% 4.1%
Rev Growth +50.5% +50.5% +4.8% +15.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 20.98M 20.98M 17.98M 18.29M
Total Equity 64.88M 64.88M 107.54M 109.94M
D/E Ratio 0.32 0.32 0.17 0.17
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -39,411,788 -24,886,140 4.13M 4.65M
Free Cash Flow 1.88M 2.75M